VANCOUVER, BC — /CNW/ — Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that… Read More
After an extensive search the Institute of Health Economics (IHE) Board of Directors has appointed Dr. Katherine (Kate) Harback as the new CEO and Executive Director for the IHE. Dr…. Read More
COLUMVI (glofitamab for injection) is the first fixed treatment duration CD20xCD3 T-cell engaging bispecific antibody approved in Canada, and globally, to treat diffuse large B-cell lymphoma[1,2,3] Authorization is based on… Read More
All-oral, once-daily, fixed-duration combination regimen authorized for first-line treatment of CLL TORONTO, ON — /CNW/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued… Read More
Generalized pustular psoriasis differs significantly from plaque psoriasis in both its disease mechanism and severity.¹ In the EFFISAYIL®-1 trial, over half of the SPEVIGO® (spesolimab)-treated patients were free of pustules,… Read More
